Postoperative sepsis

Current Anaesthesia and Critical Care

Volumn 17, Issue 1-2, 2006, Pages 65-70

  Monkhouse, Diane ^a  

^a JAMES COOK UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

Immune modulation; Immune suppression; Organ dysfunction; Sepsis; Severe sepsis; Surgery; Systemic inflammatory syndrome

Indexed keywords

ACTIVATED PROTEIN C; ANTIBIOTIC AGENT; APOLIPOPROTEIN E; C REACTIVE PROTEIN; DROTRECOGIN; HEAT SHOCK PROTEIN; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 6; LYMPHOTOXIN; PROCALCITONIN; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CLOSTRIDIUM TETANI; COMORBIDITY; DEBRIDEMENT; DEVICE REMOVAL; DISEASE SEVERITY; EARLY DIAGNOSIS; FEVER; GENETIC VARIABILITY; HEALTH PROGRAM; HOSPITAL ADMISSION; HUMAN; IMMUNE DEFICIENCY; IMMUNE RESPONSE; INCIDENCE; INFLAMMATION; LENGTH OF STAY; LEUKOCYTOSIS; MORBIDITY; MORTALITY; POSTOPERATIVE INFECTION; PREDICTION; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; RESUSCITATION; SENSITIVITY AND SPECIFICITY; SEPSIS; SURGICAL DRAINAGE; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

EID: 33748428438     PISSN: 09537112     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cacc.2006.05.005     Document Type: Article

References (37)

1. Hotchkiss R.S., and Karl I.E. The pathophysiology and treatment of sepsis. N Engl J Med 348 2 (2003) 138-150
2. Angus D.C., Linde-Zwirble W.T., Lidicker J., Clermont G., Carcillo J., and Pinsky M.R. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 29 7 (2001) 1303-1310
3. Zeni F., Freeman B., and Natanson C. Anti-inflammatory therapies to treat sepsis and septic shock: a reassessment. Crit Care Med 25 7 (1997) 1095-1100
4. Faist E., Wichmann M., and Kim C. Immunosuppression and immunomodulation in surgical patients. Curr Opin Crit Care 3 (1997) 293-298
5. Bone R.C., Balk R.A., Cerra F.B., et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 101 6 (1992) 1644-1655
6. Angus D.C., and Wax R.S. Epidemiology of sepsis: an update. Crit Care Med 29 Suppl. 7 (2001) S109-S116
7. Padkin A., Goldfrad C., Brady A.R., Young D., Black N., and Rowan K. Epidemiology of severe sepsis occurring in the first 24 h in intensive care units in England, Wales, and Northern Ireland. Crit Care Med 31 9 (2003) 2332-2338
8. Case mix programme data base. London: ICNARC.
9. Mokart D., Merlin M., Sannini A., et al. Procalcitonin, interleukin 6 and systemic inflammatory response syndrome (SIRS): early markers of postoperative sepsis after major surgery. Br J Anaesth 94 6 (2005) 767-773
10. Mokart D., Leone M., Sannini A., et al. Predictive perioperative factors for developing severe sepsis after major surgery. Br J Anaesth 95 6 (2005) 776-781
11. Stafford R.E., and Weigelt J.A. Surgical infections in the critically ill. Curr Opin Crit Care 8 5 (2002) 449-452
12. Angele M.K., Schwacha M.G., Ayala A., and Chaudry I.H. Effect of gender and sex hormones on immune responses following shock. Shock 14 2 (2000) 81-90
13. Weighardt H., Heidecke C.D., Westerholt A., et al. Impaired monocyte IL-12 production before surgery as a predictive factor for the lethal outcome of postoperative sepsis. Ann Surg 235 4 (2002) 560-567
14. Holmes C.L., Russell J.A., and Walley K.R. Genetic polymorphisms in sepsis and septic shock: role in prognosis and potential for therapy. Chest 124 3 (2003) 1103-1115
15. Moretti E.W., Morris R.W., Podgoreanu M., et al. APOE polymorphism is associated with risk of severe sepsis in surgical patients. Crit Care Med 33 11 (2005) 2521-2526
16. Windsor A.C., Klava A., Somers S.S., Guillou P.J., and Reynolds J.V. Manipulation of local and systemic host defence in the prevention of perioperative sepsis. Br J Surg 82 11 (1995) 1460-1467
17. Wakefield C.H., Carey P.D., Foulds S., Monson J.R., and Guillou P.J. Polymorphonuclear leukocyte activation. An early marker of the postsurgical sepsis response. Arch Surg 128 4 (1993) 390-395
18. Wakefield C.H., Carey P.D., Foulds S., Monson J.R., and Guillou P.J. Changes in major histocompatibility complex class II expression in monocytes and T cells of patients developing infection after surgery. Br J Surg 80 2 (1993) 205-209
19. Ayala A., Perin M.M., and Chaudry I.H. Increased susceptibility to sepsis following haemorrhage: defective Kupffer cell-mediated antigen presentation. Surgical Forum 40 (1989) 102-104
20. Tartter P.I. Blood transfusion and infectious complications following colorectal cancer surgery. Br J Surg 75 8 (1988) 789-792
21. Crabtree T.D., Pelletier S.J., Antevil J.L., Gleason T.G., Pruett T.L., and Sawyer R.G. Cohort study of fever and leukocytosis as diagnostic and prognostic indicators in infected surgical patients. World J Surg 25 6 (2001) 739-744
22. Gleckman R., and Hibert D. Afebrile bacteremia: a phenomenon in geriatric patients. JAMA 248 12 (1982) 1478-1481
23. Martin C., Boisson C., Haccoun M., Thomachot L., and Mege J.L. Patterns of cytokine evolution (tumor necrosis factor-alpha and interleukin-6) after septic shock, hemorrhagic shock, and severe trauma. Crit Care Med 25 11 (1997) 1813-1819
24. Mokart D., Capo C., Blache J.L., et al. Early postoperative compensatory anti-inflammatory response syndrome is associated with septic complications after major surgical trauma in patients with cancer. Br J Surg 89 11 (2002) 1450-1456
25. Clec'h C., Fosse J.P., Karoubi P., et al. Differential diagnostic value of procalcitonin in surgical and medical patients with septic shock. Crit Care Med 34 1 (2006) 102-107
26. Dellinger R.P., Carlet J.M., Masur H., et al. Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Intensive Care Med 30 4 (2004) 536-555
27. Gao F., Melody T., Daniels D.F., Giles S., and Fox S. The impact of compliance with 6-hour and 24-hour sepsis bundles on hospital mortality in patients with severe sepsis: a prospective observational study. Crit Care 9 6 (2005) R764-R770
28. Rivers E., Nguyen B., Havstad S., et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 345 19 (2001) 1368-1377
29. Boyd O., Grounds R.M., and Bennett E.D. A randomized clinical trial of the effect of deliberate perioperative increase of oxygen delivery on mortality in high-risk surgical patients. JAMA 270 22 (1993) 2699-2707
30. Pearse R., Dawson D., Fawcett J., Rhodes A., Grounds R.M., and Bennett E.D. Early goal-directed therapy after major surgery reduces complications and duration of hospital stay. A randomised, controlled trial. Crit Care 9 6 (2005) R687-R693
31. Pearse R., Dawson D., Fawcett J., Rhodes A., Grounds R.M., and Bennett E.D. Changes in central venous saturation after major surgery, and association with outcome. Crit Care 9 6 (2005) R694-R699
32. Marshall J.C., Maier R.V., Jimenez M., and Dellinger E.P. Source control in the management of severe sepsis and septic shock: an evidence-based review. Crit Care Med 32 Suppl. 11 (2004) S513-S526
33. Danielson D., and West M.A. Recent developments in clinical management of surgical sepsis. Curr Opin Crit Care 7 5 (2001) 367-370
34. Garnacho-Montero J., Garcia-Garmendia J.L., Barrero-Almodovar A., Jimenez-Jimenez F.J., Perez-Paredes C., and Ortiz-Leyba C. Impact of adequate empirical antibiotic therapy on the outcome of patients admitted to the intensive care unit with sepsis. Crit Care Med 31 12 (2003) 2742-2751
35. Matthay M.A. Severe sepsis-a new treatment with both anticoagulant and antiinflammatory properties. N Engl J Med 344 10 (2001) 759-762
36. Bernard G.R., Vincent J.L., Laterre P.F., et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 344 10 (2001) 699-709
37. Barie P.S., Williams M.D., McCollam J.S., et al. Benefit/risk profile of drotrecogin alfa (activated) in surgical patients with severe sepsis. Am J Surg 188 3 (2004) 212-220